Title: Geographic atrophy progression in clinical practice: before and after pegcetacoplan

Presenter:
Jessica Cao

Background

- Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) is a leading cause of irreversible vision loss
- Pegcetacoplan (Syfovre, Apellis) is an FDA-approved GA treatment
- Limited data on effects of pegcetacoplan on GA in routine clinical practice

Methods

- Clinical for patients who received ≥ 3 pegcetacoplan injections with ≥ 5 years of clinical visits prior to dosing
- GA lesion area calculated via optical coherence tomography (OCT) using RetinAI Discovery, an artificial intelligence software platform (Ikerian AG)
- Timeframe: October 17, 2017 – April 1, 2024; 5 years before pegcetacoplan initiation through 9 months after pegcetacoplan initiation



Pegcetacoplan may reduce RPE and EZ depletion rates

Figure 1. Progression of RPE and EZ depletion area



Results & Discussion

Table 1. Ocular characteristics at baseline

Characteristic		Distribution
BRVA, logMAR	Mean (SD) [Snellen approximate]	0.49 (0.47) [20/63]
	20/40 or better	74 (44.0%)
	20/40 to 20/200	77 (45.8%)
	20/200 or worse	17 (10.1%)
IOP, mean (SD) mmHg		15.3 (3.3)
Phakic status	Phakic	43 (25.6%)
	Pseudophakic	125 (74.4%)
Glaucoma	Yes	18 (10.7%)
	No	150 (89.3%)

Table 2. Treatment characteristics throughout follow-up

Characteristic		Count
Pegcetacoplan injections, mean (SD)		6.1 (1.4)
Pegcetacoplan injection interval, mean (SD) weeks		7.4 (0.9)
Adverse events after pegcetacoplan initiation	nAMD	2 (11.7%)
	Endophthalmitis	1 (0.6%)
	Intraocular inflammation	2 (1.2%)
Anti-VEGF treatment interval 6 months before pegcetacoplan initiation, mean (SD) weeks		7.6 (2.7)
Anti-VEGF treatment interval 9 months after pegcetacoplan initiation, mean (SD) weeks		6.7 (1.2)

- Progressive visual decline concurrent with apparent reduction of GA lesion growth over time appears consistent with clinical trial data
- Safety events (i.e. development of new nAMD and intraocular inflammation) were observed
- Larger datasets required for more complete understanding of efficacy and safety outcomes with pegcetacoplan treatment in routine clinical practice
- Additional analyses needed to confirm advanced segmentation algorithm; current imaging analysis output is preliminary

RCA Research

Retina Consultants of Texas™

retinai

Jessica A. Cao; Calvin W. Wong; Sandro De Zanet; Natasa Jovic; Patrick Steiner; Sagar B. Patel; Samuel Minaker; Mathew W. MacCumber; David M. Brown; Hasenin Al-khersan, Charles C. Wykoff